All Type of News
Kyowa Hakko Kirin’s Neulasta meeting better health insurance benefits
The health insurance standards of Kyowa Hakko Kirin Korea’s Neulasta Prefilled Syringe(generic name: pegfilgrastim) has been partially extensively applied since 1 April.
Neulasta is a daily long-acting drug out of gr...
Disclosure of 207 categories for uninsured medical service fees in 2017
The Ministry of Health and Welfare(Minuster Neung-Hoo Park) will unveil the ‘2018 Uninsured Medical Service Fees by Hospital’ which investigated and analyzed the current conditions by the Health Insurance Review and A...
528 medicines newly approved on 1st quarter while 8 of 10 were generic
This 1st quarter, 392 ETC medicines and 135 common drugs, totaling 528 products, were approved, and 8 of 10 approved products were generic drugs.
According to the Ministry of Food and Drug Safety’s Online Library, th...
Experiencing pains 9 months before serial number system
9 months ahead of the grace period for the real-time serial number reporting system on pharmaceutical distribution companies, people are concerning about the system because the industrial committee which should raise ...
MOHW put KRW 432.4 billion to nurture pharma industry this year
The Ministry of Health and Welfare will put KRW 432.4 billion, which is increased by KRW 53.5 billion compare to the last year, into nurturing the pharmaceutical industry this year.
The government has newly organized...
Huons acquires approval of ‘Elravie’ filler products in Indonesia
Huons(CEO Ki-Ahn Um), a subsidiary of Huons Global, announced ‘Elravie,’ a hyaluronic acid filler of Humedix, one of companies under the group, recently acquired Indonesian approval and would go on an expedition of ex...
Remsima turned over in market share against original medicine for first time as biosimilar
Remsima and Truxima are raising its share in the European market.
According to Celltrion Healthcare, ‘Remsima(generic name: infliximab),’ a biosimilar for the treatment of autoimmune disease, and ‘Truxima(generic nam...
Listed pharmas recording weakened cash flow from operating activities decreased by 20%
Listed pharmaceutical companies reported had a 20% decrease in cash flow from operating activities last year compared to 2015.
Yakup Shinmoon(www.yakup.com) analyzed 2017 audit reports(consolidated) 64 listed pharmac...
Hanmi Pharm, “ZAI Lab will return Chinese license of olmutinib, targeted cancer therapy”
ZAI Lab decided to return the license of ‘olmutinib(HM61713),’ a targeted therapy for cancer, due to the company’s change of new drug development strategy in Chana, and Hanmi Pharm announced on the 29th that Hanmi Pha...
Which are ‘representative’ pharmas of Korea in the current era?
While Korean pharmaceutical companies are fiercely competing each other first to become a global pharmaceutical company, people are also paying attention which will become ‘representative’ Korean pharmaceutical compan...
